-DOCSTART-	O

Title	O
:	O
Music	B-I
therapy	I-I
in	O
moderate	O
and	O
severe	O
dementia	O
of	O
Alzheimer	O
'	O
s	O
type	O
:	O
a	O
case	O
-	O
control	O
study	O
.	O

METHODS	O
:	O
This	O
case	O
-	O
control	O
study	O
was	O
carried	O
out	O
by	O
qualified	O
music	O
therapists	O
in	O
two	O
nursing	O
homes	O
and	O
two	O
psychogeriatric	O
wards	O
.	O

The	O
participants	O
were	O
38	B-P
patients	I-P
with	I-P
moderate	I-P
or	I-P
severe	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
(	I-P
AD	I-P
)	I-P
assigned	O
randomly	O
to	O
a	B-I
music	I-I
therapy	I-I
group	O
and	O
a	O
control	O
group	O
.	O

-DOCSTART-	O

Title	O
:	O
Keep	O
music	O
live	O
:	O
music	B-I
and	O
the	O
alleviation	O
of	O
apathy	O
in	O
dementia	B-P
subjects	I-P
.	O

METHODS	O
:	O
Thirty	B-P
-	I-P
two	I-P
subjects	I-P
meeting	I-P
ICD	I-P
-	I-P
10	I-P
diagnostic	I-P
criteria	I-P
for	I-P
moderate	I-P
to	I-P
severe	I-P
dementia	I-P
and	I-P
fulfilling	I-P
diagnostic	I-P
criteria	I-P
for	I-P
apathy	I-P
were	O
exposed	O
to	O
live	B-I
interactive	I-I
music	I-I
,	O
passive	B-I
pre	I-I
-	I-I
recorded	I-I
music	I-I
or	O
silence	B-I
for	O
30	O
minutes	O
.	O

Each	O
subject	O
was	O
randomized	O
to	O
30	O
-	O
minute	O
music	O
or	O
silent	O
periods	O
and	O
was	O
video	O
recorded	O
and	O
the	O
muted	O
recording	O
analyzed	O
every	O
3	O
minutes	O
using	O
dementia	B-O
care	I-O
mapping	I-O
to	O
assess	O
the	B-O
quality	I-O
of	I-O
engagement	I-O
to	I-O
the	I-O
blinded	I-O
music	I-O
intervention	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Memantine	B-I
treatment	I-I
in	O
mild	O
to	O
moderate	O
Alzheimer	O
disease	O
:	O
a	O
24	O
-	O
week	O
randomized	O
,	O
controlled	O
trial	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
clinical	O
trial	O
conducted	O
at	O
42	O
U	O
.	O
S	O
.	O
sites	O
.	O

Participants	O
were	O
403	B-P
outpatients	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
AD	I-P
and	I-P
Mini	I-P
-	I-P
Mental	I-P
State	I-P
Examination	I-P
scores	I-P
of	I-P
10	I-P
-	I-P
22	I-P
randomized	O
to	O
memantine	B-I
(	O
20	O
mg	O
/	O
day	O
;	O
N=201	O
)	O
or	O
placebo	B-C
(	O
N=202	O
)	O
for	O
24	O
weeks	O
.	O

Primary	O
outcomes	O
were	O
change	O
from	O
baseline	O
at	O
24	O
weeks	O
on	O
the	B-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
Cognitive	I-O
Subscale	I-O
(	I-O
ADAS	I-O
-	I-O
cog	I-O
)	I-O
,	O
a	O
measure	O
of	O
cognition	B-O
,	O
and	O
on	O
the	B-O
Clinician	I-O
'	I-O
s	I-O
Interview	I-O
-	I-O
Based	I-O
Impression	I-O
of	I-O
Change	I-O
Plus	I-O
Caregiver	I-O
Input	I-O
(	I-O
CIBIC	I-O
-	I-O
Plus	I-O
)	I-O
,	O
a	O
global	O
measure	O
.	O

Secondary	O
outcomes	O
included	O
change	O
on	O
the	B-O
Neuropsychiatric	I-O
Inventory	I-O
(	I-O
NPI	I-O
)	I-O
and	O
the	B-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Cooperative	I-O
Study	I-O
Activities	I-O
of	I-O
Daily	I-O
Living	I-O
Inventory	I-O
(	I-O
ADCS	I-O
-	I-O
ADL	I-O
(	I-O
23	I-O
)	I-O
)	I-O
,	O
measures	O
of	O
behavior	B-O
and	O
function	B-O
,	O
respectively	O
.	O

-DOCSTART-	O

Title	O
:	O
Safety	O
and	O
efficacy	O
of	O
donepezil	B-I
in	O
African	B-P
Americans	I-P
with	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
Efficacy	O
was	O
assessed	O
via	O
the	B-O
Mini	I-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
,	O
Clinician	B-O
'	I-O
s	I-O
Interview	I-O
-	I-O
Based	I-O
Impression	I-O
of	I-O
Change	I-O
-	I-O
Plus	I-O
interview	I-O
with	I-O
the	I-O
patient	I-O
and	I-O
caregiver	I-O
(	I-O
CIBIC	I-O
-	I-O
Plus	I-O
)	I-O
and	O
Fuld	B-O
Object	I-O
Memory	I-O
Evaluation	I-O
(	I-O
FOME	I-O
)	I-O
,	O
a	O
measure	O
that	O
has	O
been	O
validated	O
for	O
use	O
with	O
elderly	O
African	O
Americans	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
Phase	O
II	O
study	O
targeting	O
amyloid	O
-	O
beta	O
with	O
3	B-I
APS	I-I
in	O
mild	O
-	O
to	O
-	O
moderate	O
Alzheimer	O
disease	O
.	O

METHODS	O
:	O
We	O
assessed	O
the	O
safety	O
,	O
tolerability	O
,	O
and	O
pharmacokinetic	O
/	O
pharmacodynamic	O
effect	O
of	O
3	B-I
APS	I-I
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
Phase	O
II	O
study	O
in	O
which	O
58	B-P
subjects	I-P
with	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
AD	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
placebo	B-C
or	O
3	B-I
APS	I-I
50	O
,	O
100	O
,	O
or	O
150	O
mg	O
BID	O
for	O
3	O
months	O
.	O

At	O
the	O
end	O
of	O
the	O
double	O
-	O
blind	O
phase	O
,	O
42	O
of	O
these	O
subjects	O
entered	O
an	O
open	O
-	O
label	O
phase	O
in	O
which	O
they	O
received	O
3	B-I
APS	I-I
150	O
mg	O
BID	O
for	O
17	O
months	O
.	O

Assessments	O
included	O
plasma	B-O
and	O
CSF	B-O
3	I-O
APS	I-O
concentrations	I-O
,	O
CSF	B-O
levels	I-O
of	I-O
Abeta	I-O
(	I-O
Abeta	I-O
(	I-O
40	I-O
)	I-O
and	I-O
Abeta	I-O
(	I-O
42	I-O
)	I-O
)	I-O
,	O
and	O
total	B-O
tau	I-O
,	O
as	O
well	O
as	O
cognitive	B-O
(	O
Alzheimer	B-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
cognitive	I-O
subscale	I-O
,	O
Mini	B-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
)	O
and	O
clinical	B-O
(	O
Clinical	B-O
Dementia	I-O
Rating	I-O
scale	I-O
-	I-O
Sum	I-O
of	I-O
Boxes	I-O
)	O
measures	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
statins	B-I
on	O
Alzheimer	O
'	O
s	O
disease	O
biomarkers	O
in	O
cerebrospinal	O
fluid	O
.	O

METHODS	O
:	O
We	O
measured	O
levels	B-O
of	I-O
cerebrospinal	I-O
fluid	I-O
(	I-O
CSF	I-O
)	I-O
AD	I-O
biomarkers	I-O
following	O
14	O
weeks	O
of	O
treatment	O
with	O
simvastatin	B-I
(	O
a	B-I
CNS	I-I
permeant	I-I
statin	I-I
;	O
n=10	O
)	O
at	O
40	O
mg	O
/	O
day	O
or	O
pravastatin	B-I
(	O
a	B-I
CNS	I-I
impermeant	I-I
statin	I-I
;	O
n=13	O
)	O
at	O
80	O
mg	O
/	O
day	O
in	O
hypercholesterolemic	B-P
subjects	I-P
without	I-P
dementia	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Exercise	B-I
program	I-I
for	O
nursing	B-P
home	I-P
residents	I-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
:	O
a	O
1	O
-	O
year	O
randomized	O
,	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Randomized	O
,	O
controlled	O
trial	O
.	O

Five	O
nursing	O
homes	O
.	O

One	B-P
hundred	I-P
thirty	I-P
-	I-P
four	I-P
ambulatory	I-P
patients	I-P
with	I-P
mild	I-P
to	I-P
severe	I-P
AD	I-P
.	O

Collective	B-I
exercise	I-I
program	I-I
(	O
1	B-I
hour	I-I
,	I-I
twice	I-I
weekly	I-I
of	I-I
walk	I-I
,	O
strength	B-I
,	O
balance	B-I
,	O
and	O
flexibility	B-I
training	I-I
)	O
or	O
routine	B-C
medical	I-C
care	I-C
for	O
12	O
months	O
.	O

ADLs	B-O
were	O
assessed	O
using	O
the	B-O
Katz	I-O
Index	I-O
of	I-O
ADLs	I-O
.	O

Physical	B-O
performance	I-O
was	O
evaluated	O
using	O
6	B-O
-	I-O
meter	I-O
walking	I-O
speed	I-O
,	O
the	B-O
get	I-O
-	I-O
up	I-O
-	I-O
and	I-O
-	I-O
go	I-O
test	I-O
,	O
and	O
the	B-O
one	I-O
-	I-O
leg	I-O
-	I-O
balance	I-O
test	I-O
.	O

Behavioral	B-O
disturbance	I-O
,	O
depression	B-O
,	O
and	O
nutritional	B-O
status	I-O
were	O
evaluated	O
using	O
the	B-O
Neuropsychiatric	I-O
Inventory	I-O
,	O
the	B-O
Montgomery	I-O
and	I-O
Asberg	I-O
Depression	I-O
Rating	I-O
Scale	I-O
,	O
and	O
the	B-O
Mini	I-O
-	I-O
Nutritional	I-O
Assessment	I-O
.	O

For	O
each	O
outcome	O
measure	O
,	O
the	O
mean	O
change	O
from	O
baseline	O
to	O
12	O
months	O
was	O
calculated	O
using	O
intention	O
-	O
to	O
-	O
treat	O
analysis	O
.	O

-DOCSTART-	O

Title	O
:	O
Open	O
label	O
,	O
multicenter	O
,	O
28	O
-	O
week	O
extension	O
study	O
of	O
the	O
safety	O
and	O
tolerability	O
of	O
memantine	B-I
in	O
patients	B-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
This	O
28	O
-	O
week	O
study	O
enrolled	O
314	B-P
patients	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
AD	I-P
who	I-P
had	I-P
completed	I-P
a	I-P
24	I-P
-	I-P
week	I-P
,	I-P
double	I-P
-	I-P
blind	I-P
,	I-P
placebo	I-P
-	I-P
controlled	I-P
lead	I-P
-	I-P
in	I-P
clinical	I-P
trial	I-P
of	I-P
memantine	I-P
in	I-P
AD	I-P
.	O

Following	O
an	O
8	O
-	O
week	O
double	O
-	O
blind	O
dose	O
titration	O
phase	O
(	O
used	O
to	O
assess	O
the	O
tolerability	O
of	O
different	O
dosing	O
regimens	O
)	O
,	O
subjects	O
were	O
assigned	O
to	O
continuous	B-I
open	I-I
label	I-I
memantine	I-I
(	O
10	O
mg	O
,	O
bi	O
.	O
d	O
.	O
)	O
treatment	O
for	O
20	O
weeks	O
.	O

Safety	O
outcome	O
measures	O
included	O
treatment	B-O
-	I-O
emergent	I-O
adverse	I-O
events	I-O
(	I-O
AEs	I-O
)	I-O
,	O
deaths	B-O
,	O
vital	B-O
signs	I-O
,	O
electrocardiograms	B-O
,	O
and	O
laboratory	B-O
parameters	I-O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
six	O
-	O
month	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
study	O
of	O
a	B-I
transdermal	I-I
patch	I-I
in	O
Alzheimer	O
'	O
s	O
disease	O
-	O
-	O
rivastigmine	B-I
patch	I-I
versus	O
capsule	B-I
.	O

METHODS	O
:	O
In	O
this	O
24	O
-	O
week	O
,	O
multicenter	O
,	O
double	O
-	O
blind	O
,	O
double	O
-	O
dummy	O
,	O
placebo	O
-	O
and	O
active	O
-	O
controlled	O
trial	O
,	O
patients	B-P
with	I-P
probable	I-P
AD	I-P
were	O
randomized	O
to	O
one	O
of	O
four	O
treatment	O
groups	O
:	O
12	B-I
mg	I-I
/	I-I
day	I-I
rivastigmine	I-I
capsules	I-I
;	O
10	B-I
cm2	I-I
(	I-I
9	I-I
.	I-I
5	I-I
mg	I-I
/	I-I
24	I-I
h	I-I
)	I-I
rivastigmine	I-I
patch	I-I
;	O
20	B-I
cm	I-I
(	I-I
2	I-I
)	I-I
(	I-I
17	I-I
.	I-I
4	I-I
mg	I-I
/	I-I
24	I-I
h	I-I
)	I-I
rivastigmine	I-I
patch	I-I
;	O
or	O
placebo	B-C
.	O

Primary	O
efficacy	O
measures	O
were	O
the	B-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
Cognitive	I-O
subscale	I-O
(	I-O
ADAS	I-O
-	I-O
Cog	I-O
)	I-O
and	O
Alzheimer	B-O
'	I-O
s	I-O
Disease	I-O
Cooperative	I-O
Study	I-O
-	I-O
-	I-O
Clinical	I-O
Global	I-O
Impression	I-O
of	I-O
Change	I-O
(	I-O
ADCS	I-O
-	I-O
CGIC	I-O
)	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Antiaggressive	O
effect	O
of	O
cyproterone	B-I
versus	O
haloperidol	B-I
in	O
Alzheimer	O
'	O
s	O
disease	O
:	O
a	O
randomized	O
double	O
-	O
blind	O
pilot	O
study	O
.	O

METHODS	O
:	O
The	O
subjects	O
were	O
27	B-P
elderly	I-P
patients	I-P
referred	I-P
to	I-P
the	I-P
University	I-P
Hospital	I-P
of	I-P
Guadalajara	I-P
Psychogeriatric	I-P
Clinic	I-P
diagnosed	I-P
with	I-P
AD	I-P
and	I-P
associated	I-P
aggressive	I-P
behavior	I-P
(	I-P
mean	I-P
Staff	I-P
Observation	I-P
Aggression	I-P
Scale	I-P
[	I-P
SOAS	I-P
]	I-P
score	I-P
>	I-P
or=2	I-P
)	I-P
.	O

Each	O
patient	O
underwent	O
a	O
15	O
-	O
day	O
washout	O
for	O
psychotropics	O
and	O
then	O
was	O
randomly	O
assigned	O
to	O
receive	O
stable	O
doses	O
of	O
either	O
cyproterone	B-I
(	O
100	O
mg	O
/	O
day	O
)	O
or	O
haloperidol	B-I
(	O
2	O
mg	O
/	O
day	O
)	O
for	O
90	O
days	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
the	B-O
SOAS	I-O
score	I-O
.	O

This	O
trial	O
was	O
conducted	O
between	O
October	O
27	O
,	O
1993	O
,	O
and	O
March	O
24	O
,	O
1998	O
.	O

-DOCSTART-	O

Title	O
:	O
Key	O
lessons	O
learned	O
from	O
short	O
-	O
term	O
treatment	O
trials	O
of	O
cholinesterase	B-I
inhibitors	I-I
for	O
amnestic	O
MCI	O
.	O

METHODS	O
:	O
The	O
study	O
was	O
a	O
24	O
-	O
week	O
placebo	O
-	O
controlled	O
trial	O
designed	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
donepezil	B-I
HCl	I-I
(	I-I
donepezil	I-I
)	I-I
in	O
the	O
treatment	O
of	O
cognitive	O
impairment	O
in	O
subjects	B-P
with	I-P
MCI	I-P
.	O

Primary	O
outcome	O
measures	O
were	O
the	B-O
NYU	I-O
Paragraphs	I-O
Test	I-O
and	O
the	B-O
ADCS	I-O
Clinicians	I-O
Global	I-O
-	I-O
Impression	I-O
of	I-O
Change	I-O
in	O
the	O
intent	O
-	O
to	O
-	O
treat	O
last	O
-	O
observation	O
-	O
carried	O
-	O
forward	O
group	O
.	O

-DOCSTART-	O

Title	O
:	O
Intranasal	B-I
insulin	I-I
improves	O
cognition	O
and	O
modulates	O
beta	O
-	O
amyloid	O
in	O
early	O
AD	O
.	O

METHODS	O
:	O
Twenty	B-P
-	I-P
five	I-P
participants	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
placebo	B-I
(	O
n	O
=	O
12	O
)	O
or	O
20	B-I
IU	I-I
BID	I-I
intranasal	I-I
insulin	I-I
treatment	I-I
(	O
n	O
=	O
13	O
)	O
using	O
an	O
electronic	O
atomizer	O
,	O
and	O
24	O
participants	O
completed	O
the	O
study	O
.	O

Participants	O
,	O
caregivers	O
,	O
and	O
all	O
clinical	O
evaluators	O
were	O
blinded	O
to	O
treatment	O
assignment	O
.	O

Cognitive	O
measures	O
and	O
blood	O
were	O
obtained	O
at	O
baseline	O
and	O
after	O
21	O
days	O
of	O
treatment	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
views	O
of	O
Alzheimer	B-P
disease	I-P
patients	I-P
and	I-P
their	I-P
study	I-P
partners	I-P
on	O
proxy	O
consent	O
for	O
clinical	O
trial	O
enrollment	O
.	O

METHODS	O
:	O
Cross	O
-	O
sectional	O
interview	O
.	O

At	O
the	O
13	O
study	O
sites	O
of	O
a	O
randomized	O
and	O
placebo	O
controlled	O
study	O
of	O
simvastatin	B-I
for	O
the	O
treatment	O
of	O
AD	O
.	O

Patients	B-P
with	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
AD	I-P
and	I-P
their	I-P
study	I-P
partners	I-P
enrolled	O
in	O
an	O
Alzheimer	O
'	O
s	O
Disease	O
Cooperative	O
Study	O
trial	O
of	O
simvastatin	B-I
.	O

Interviews	O
to	O
assess	O
how	B-O
participants	I-O
made	I-O
the	I-O
decision	I-O
to	I-O
enroll	I-O
in	I-O
a	I-O
randomized	I-O
controlled	I-O
trial	I-O
and	O
their	B-O
attitudes	I-O
on	I-O
proxy	I-O
consent	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Safety	O
and	O
efficacy	O
of	O
galantamine	B-I
in	O
subjects	B-P
with	I-P
mild	I-P
cognitive	I-P
impairment	I-P
.	O

METHODS	O
:	O
In	O
two	O
studies	O
,	O
2	B-P
,	I-P
048	I-P
subjects	I-P
,	I-P
990	I-P
in	I-P
Study	I-P
1	I-P
and	I-P
1	I-P
,	I-P
058	I-P
in	I-P
Study	I-P
2	I-P
,	I-P
with	I-P
a	I-P
Clinical	I-P
Dementia	I-P
Rating	I-P
(	I-P
CDR	I-P
)	I-P
=	I-P
0	I-P
.	I-P
5	I-P
,	I-P
CDR	I-P
memory	I-P
score	I-P
>	I-P
or	I-P
=0	I-P
.	I-P
5	I-P
,	I-P
without	I-P
dementia	I-P
were	O
randomized	O
to	O
double	B-I
-	I-I
blind	I-I
galantamine	I-I
(	O
16	O
-	O
24	O
mg	O
/	O
day	O
)	O
or	O
placebo	B-C
for	O
24	O
months	O
.	O

Primary	O
efficacy	O
endpoint	O
at	O
month	O
24	O
was	O
number	B-O
(	I-O
%	I-O
)	I-O
of	I-O
subjects	I-O
who	I-O
converted	I-O
from	I-O
MCI	I-O
to	I-O
dementia	I-O
(	I-O
CDR	I-O
>	I-O
or	I-O
=	I-O
1	I-O
.	I-O
0	I-O
)	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Cognitive	O
effects	O
of	O
treating	B-I
obstructive	I-I
sleep	I-I
apnea	I-I
in	O
Alzheimer	O
'	O
s	O
disease	O
:	O
a	O
randomized	O
controlled	O
study	O
.	O

METHODS	O
:	O
Randomized	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
trial	O
.	O

Participants	O
were	O
randomized	O
to	O
therapeutic	B-I
CPAP	I-I
for	O
6	O
weeks	O
or	O
placebo	B-C
CPAP	I-C
for	O
3	O
weeks	O
followed	O
by	O
therapeutic	B-I
CPAP	I-I
for	O
3	O
weeks	O
.	O

General	O
clinical	O
research	O
center	O
.	O

Fifty	B-P
-	I-P
two	I-P
men	I-P
and	I-P
women	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
AD	I-P
and	I-P
OSA	I-P
.	O

CPAP	B-I
.	O

A	B-O
complete	I-O
neuropsychological	I-O
test	I-O
battery	I-O
was	O
administered	O
before	O
treatment	O
and	O
at	O
3	O
and	O
at	O
6	O
weeks	O
.	O

